The addition of anifrolumab to usual lupus treatment has been shown to improve disease activity and reduce glucocorticoid use in adult patients with moderate to severely active SLE. The phase 3 TULIP-2 trial assessed the effect of the monoclonal antibody- which inhibits signalling through the type I interferon receptor – in 362 patients from 16 ...
Monoclonal antibody anifrolumab shows success against lupus
By Mardi Chapman
20 Jan 2020